Anna-Klara Pettersson, Giola Santoni, Jacinth Yan, Cecilia Radkiewicz, Shaohua Xie, Helgi Birgisson, Eivind Ness-Jensen, My von Euler-Chelpin, Joonas H. Kauppila & Jesper Lagergren (2023) Cohort profile: Nordic Helicobacter Pylori eradication project (NordHePEP), Scandinavian Journal of Gastroenterology, 58:5, 453-459, DOI: 10.1080/00365521.2022.2144435
Cohort profile : Nordic Helicobacter Pylori eradication project (NordHePEP)
|Author:||Pettersson, Anna-Klara1; Santoni, Giola1; Yan, Jacinth2;|
1Department of Molecular medicine and Surgery, Karolinska Institutet, Upper Gastrointestinal Surgery, Stockholm, Sweden
2Division of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
3The Icelandic Cancer Registry, Reykjavik, Iceland
4Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Levanger, Norway
5Medical Department, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway
6Department of Public Health, University of Copenhagen, Copenhagen, Denmark
7Department of Surgery, Oulu University Hospital and University of Oulu, Oulu, Finland
8School of Cancer and Pharmaceutical Sciences, King’s College London, London, UK
|Online Access:||PDF Full Text (PDF, 1.8 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe2023070585032
|Publish Date:|| 2023-07-05
Purpose: This cohort description presents the Nordic Helicobacter Pylori Eradication Project (NordHePEP), a population-based cohort of patients having received eradication treatment for Helicobacter pylori (HP). The cohort is created with the main purpose of examining whether and to what extent HP eradication treatment influences the risk of gastrointestinal cancer.
Participants: NordHePEP includes all adults (aged ≥18 years) having been prescribed and dispensed HP eradication treatment according to the nationwide complete drug registries in any of the five Nordic countries (Denmark, Finland, Iceland, Norway, or Sweden) between 1994 and 2020 (start and end year varies between countries). We have retrieved and merged individual-level data from multiple national registries, including drug, patient, cancer, population, and death registries.
Findings: The cohort includes 674,771 patients having received HP eradication treatment. During up to 23 years of follow-up, 59,292 (8.8%) participants were diagnosed with cancer (non-melanoma skin cancer excluded), whereof 15,496 (2.3%) in the gastrointestinal tract.
Future plans: We will analyse HP eradication treatment in relation to gastrointestinal cancer risk. Standardised incidence ratios will be calculated as the observed cancer incidence in the cohort divided by the expected cancer incidence, derived from the background population of the corresponding age, sex, and calendar year.
Scandinavian journal of gastroenterology
|Pages:||453 - 459|
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
3121 General medicine, internal medicine and other clinical medicine
Specific research projects based on NordHePEP data are funded by Sjöberg Foundation (contract number 2021-01-14:9), Swedish Cancer Society (21 1489), Nordic Cancer Union [R278-A15884], and Stockholm County Council [501242 and 2020-0734]. The funding organisations are not involved in the design or execution of the cohort or the planned studies.
© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.